

#### PATIENT INFORMATION

Name:	Date of Birth:	<input type="radio"/> Male <input type="radio"/> Female
Address:	City:	State:
Phone:	Alt Phone:	Email:
SS #:	Primary Language:	Emergency Contact:

#### PRESCRIBER INFORMATION

Prescribing Practitioner:	NPI#:			
Supervising Physician:	NPI#:			
Address:	City:	State:	Zip:	Tax ID:
Phone:	Fax:	Office Contact:		

#### PRESCRIPTION INFORMATION

<b>Needs by Date:</b>	<b>Ship to:</b> <input type="radio"/> Patients home <input type="radio"/> Prescriber 1st order only <input type="radio"/> Prescriber all orders <input type="radio"/> Other		
Drug	Dose	Direction & Quantities	Refills
<input type="radio"/> <b>Adbry™</b>	<input type="radio"/> 150 mg pre-filled syringe	<input type="radio"/> INITIAL: 600 mg (four 150 mg injections) SQ (Quantity 4) <input type="radio"/> MAINTENANCE: 300 mg (two 150 mg injections) SQ every other week. (Quantity 4) 300 mg every 4 weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment.	
<input type="radio"/> <b>Dupixent®</b>	<input type="radio"/> 300 mg Pre-filled Syringe	<b>ADULT:</b>	
	<input type="radio"/> 300 mg Pen	<input type="radio"/> INITIAL: Inject 600 mg SQ on day 1 (Quantity: 2) <input type="radio"/> MAINTENANCE: Inject 300 mg every <b>other</b> week starting at day 15 (Quantity: 2)	
	<input type="radio"/> 300 mg Pre-filled Syringe	<b>PEDIATRIC (ages 6 to 17): ***WEIGHT REQUIRED*** _____</b>	
	<input type="radio"/> 300 mg Pen*	<input type="radio"/> INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2).   ***Intended for weight 15kg/33lbs to <30kg/66lbs*** <input type="radio"/> MAINTENANCE: Inject 300 mg <b>every 4 weeks</b> thereafter (Quantity: 1) <input type="radio"/> INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2).   ***Intended for weight ≥60kg/132lbs*** <input type="radio"/> MAINTENANCE: Inject 300 mg every <b>other</b> week starting at day 15 (Quantity: 2)	
<input type="radio"/> <b>Eucrisa®</b>	<input type="radio"/> 2% Ointment 60 gm*	<input type="radio"/> Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)	
	<input type="radio"/> 2% Ointment 100 gm*		
<input type="radio"/> <b>Opzelura™</b>	<input type="radio"/> 1.5% Cream 60 gm*	<input type="radio"/> Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)	
<input type="radio"/> <b>Rinvoq</b>	<input type="radio"/> 15 mg tablet	<input type="radio"/> Take 15 mg once daily (Quantity 30)	
	<input type="radio"/> 30 mg tablet	<input type="radio"/> Take 30 mg once daily (Quantity 30)	
<input type="radio"/> <b>Cibinqo™</b>	<input type="radio"/> 100 mg Tablet	<input type="radio"/> Take 100 mg PO once daily (Quantity: 30)	
	<input type="radio"/> 200 mg Tablet	<input type="radio"/> Take 200 mg PO once daily (Quantity: 30) ***Intended for patients who have not achieved adequate response with 100 mg daily dose***	

#### MEDICAL INFORMATION

\*\* PLEASE FAX COPY OF PRESCRIPTION MEDICATION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY \*\*

PREVIOUS THERAPIES:	Tried & Failed (Duration)	Not Tolerated:	Contraindication:
<input type="radio"/> Methotrexate	<input type="radio"/> (_____)	<input type="radio"/>	_____
<input type="radio"/> Cyclosporine	<input type="radio"/> (_____)	<input type="radio"/>	_____
<input type="radio"/> Tacrolimus	<input type="radio"/> (_____)	<input type="radio"/>	_____
<input type="radio"/> Ultravate	<input type="radio"/> (_____)	<input type="radio"/>	_____
<input type="radio"/> Topicort	<input type="radio"/> (_____)	<input type="radio"/>	_____
PHOTOTHERAPY	Tried & Failed (Duration)	Not Tolerated:	Contraindication:
<input type="radio"/> UVA /UVB	<input type="radio"/> (_____)	<input type="radio"/>	_____
<input type="radio"/> Patient cannot afford <input type="radio"/> Photosensitivity <input type="radio"/> Risk of Skin Cancer <input type="radio"/> Distance from Office			
<input type="radio"/> L20.9 Atopic Dermatitis (Moderate to Severe)		<input type="radio"/> Other: _____	
Date of Diagnosis: ____/____/____			

**Affected Areas**

Face    Feet    Groin    Hands  
 Nails    Scalp    Other

**Scoring tool used**

BSA    EASI    ISGA    POEM  
 SCORAD \_\_\_\_% or Score: \_\_\_\_

Active TB is ruled out:    Yes    No   Date: \_\_\_\_/\_\_\_\_/\_\_\_\_   Hep B ruled out/treated:    Yes    No   Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Allergies: \_\_\_\_\_   Additional Clinical Information: \_\_\_\_\_

#### AMERICAN ACADEMY OF DERMATOLOGY CONSENSUS STATEMENT ON PSORIASIS THERAPIES

- Psoriasis is covering greater than 10% of body surface area       Psoriasis is on palms, soles, head and neck, or genitalia
- Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
- Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships.

#### INJECTION TRAINING

- Patient has received pen and injection training       Physician's office to provide injection training       Parkway Pharmacy to coordinate injection training

#### PRESCRIBING PRACTITIONER SIGNATURE

**To Prescribing Practitioner:** By signing this form and utilizing our services, you are also authorizing Parkway Pharmacy to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescribing Practitioner: \_\_\_\_\_ Date: \_\_\_\_\_

#### CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you Faxed Prescriptions will only be accepted from a prescribing practitioner.